Prostate Cancer - Results from #640

Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care. July 16, 2024

Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer. July 15, 2024

Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T. July 15, 2024

Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection. July 15, 2024

The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort. July 15, 2024

An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression. July 15, 2024

Limited Evidence of Shared Decision Making for Prostate Cancer Screening in Audio-Recorded Primary Care Visits Among Black Men and their Healthcare Providers. July 15, 2024

Transcriptome-wide association analysis identifies candidate susceptibility genes for prostate-specific antigen levels in men without prostate cancer. July 15, 2024

Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer. July 15, 2024

Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial. July 15, 2024

Impact of Anti-Discrimination Legislation on Access to Gender-affirming Care: A Commercial Claims Analysis July 12, 2024

Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. July 12, 2024

Outcomes after precision prostatectomy: safety, efficacy and transference of skills. July 12, 2024

Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer. July 12, 2024

ProsTAV, a clinically useful test in prostate cancer: an extension study. July 12, 2024

Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality. July 12, 2024

Clinical considerations for sexual and gender minorities with prostate cancer. July 12, 2024

JMJD2A promotes the development of castration-resistant prostate cancer by activating androgen receptor enhancer and inhibiting the cGAS-STING pathway. July 12, 2024

Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation. July 12, 2024

CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer. July 12, 2024

Page 33 of 1438